MIM
NMTR

MetLife Investment Management’s 9 Meters Biopharma NMTR Stock Holding History

MetLife Investment Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,238
Closed -$110K – 2577
2021
Q3 		$110K Buy
+4,238
New +$99.9K ﹤0.01% 2402

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MetLife Investment Management's NMTR Position: Q4 2021 in Review

MetLife Investment Management sold out of 9 Meters Biopharma (NMTR) in Q4 2021, closing a stake of 4,238 shares — an estimated $110K sold.

MetLife Investment Management first reported a position in NMTR in Q3 2021 and held it in 1 quarter. The position peaked at $110K in Q3 2021. 104 funds tracked by Wall St. Rank hold NMTR as of Q4 2021.

  • MetLife Investment Management reported no remaining 9 Meters Biopharma position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 4,238 9 Meters Biopharma shares in Q4 2021, an estimated $110K.
  • MetLife Investment Management first reported a position in 9 Meters Biopharma in Q3 2021 and held it in 1 quarter.
  • MetLife Investment Management's 9 Meters Biopharma position peaked at $110K in Q3 2021.
  • 104 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.